@article{de4e6874062b4210b26ce581bf98dc3c,
title = "What Clinicians Need to Know about the Development of Long-Acting Formulations",
keywords = "HIV prevention, HIV treatment, long-acting formulations, tuberculosis, viral hepatitis",
author = "Charles Flexner and Thomas, {David L.} and Polly Clayden and Susan Swindells",
note = "Funding Information: The authors would like to thank Jane McKenzie-White for expert assistance in organizing and managing the publication of this Supplement. The preparation of this manuscript was supported in part by NIH National Institute of Allergy and Infectious Diseases (NIAID) grant number R24 AI118397, Long-Acting/Extended Release Antiretroviral Research Resource Program (LEAP), www.longactinghiv. org, awarded to Johns Hopkins University. This article appears as part of the supplement “Long-Acting and Extended-Release Formulations for the Treatment and Prevention of Infectious Diseases,” sponsored by the Long-Acting/ Extended Release Antiretroviral Research Resource Program (LEAP).",
year = "2022",
month = dec,
day = "1",
doi = "10.1093/cid/ciac749",
language = "English (US)",
volume = "75",
pages = "S487--S489",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "Supplement_4",
}